Abstract: The invention provides new methods of treating patients benefiting from increased blood levels of alpha-lipoic acid. Such patients may include those suffering from various physiological disorders such as diabetic neuropathy. A dissolvable tablet, not meant to be swallowed, comprising alpha-lipoic acid in a limited release matrix provides means of administering therapeutically beneficial concentrations of alpha-lipoic acid without the commonly associated oral burn. Due to its orally dissolvable nature, this rate limiting matrix can deliver approximately IV-equivalent plasma levels of thioctic acid.

Abstract: The addition of a salt to an ALA formulation that is dissolved in the mouth unexpectedly significantly reduces the degree of burning or irritation from ALA exposure during administration. This invention is particularly useful for an oral dissolved form of administration due to the extended time of ALA exposure that is possible with such formulations. The salt-inclusive formulations of the invention can increase efficacy of the ALA administration, reduce negative side effects, or both.

Abstract: The invention provides new methods of administering alpha-lipoic acid to patients. A diffusion rate limiting matrix is utilized to buccally, lingually and/or sublingually deliver the alpha-lipoic acid. This sustained release matrix is intended for general nutritional supplementation and/or the treatment of various physiological disorders, such as diabetic neuropathy. Due to its lingual nature, this rate limiting matrix can deliver approximately IV-equivalent plasma levels of thioctic acid and is not meant to be swallowed.

Abstract: The addition of a salt to an ALA formulation that is dissolved in the mouth unexpectedly significantly reduces the degree of burning or irritation from ALA exposure during administration. This invention is particularly useful for an oral dissolved form of administration due to the extended time of ALA exposure that is possible with such formulations. The salt-inclusive formulations of the invention can increase efficacy of the ALA administration, reduce negative side effects, or both.

Abstract: The invention provides new methods of treating patients benefiting from increased blood levels of alpha-lipoic acid. Such patients may include those suffering from various physiological disorders such as diabetic neuropathy. A dissolvable tablet, not meant to be swallowed, comprising alpha-lipoic acid in a limited release matrix provides means of administering therapeutically beneficial concentrations of alpha-lipoic acid without the commonly associated oral burn. Due to its orally dissolvable nature, this rate limiting matrix can deliver approximately IV-equivalent plasma levels of thioctic acid.

Abstract: The addition of a salt to an ALA formulation that is dissolved in the mouth unexpectedly significantly reduces the degree of burning or irritation from ALA exposure during administration. This invention is particularly useful for an oral dissolved form of administration due to the extended time of ALA exposure that is possible with such formulations. The salt-inclusive formulations of the invention can increase efficacy of the ALA administration, reduce negative side effects, or both.